Skip to Main Content

Paper Details

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.
Nat Cancer
21
2022
CRISPR, Cas9, KIDINS220, PAX8, Phosphate, SLC34A2, SLC34A2-high cancer cell lines, XPR1, XPR1 messenger RNA, cancer, cancer cell lines, human, human cancer cell, human cancer cell lines, ovarian and uterine cancers, ovarian cancer, patient, patients, phosphate, tumor
Author NameAffiliation
Brenton R PaolellaBroad Institute of MIT and Harvard
Brenton R PaolellaMerck Research Laboratories
John G DoenchBroad Institute of MIT and Harvard
Federica PiccioniBroad Institute of MIT and Harvard
Federica PiccioniMerck Research Laboratories
David E RootBroad Institute of MIT and Harvard
David E RootBroad Institute of MIT and Harvard
Jesse S BoehmBroad Institute of MIT and Harvard
Jesse S BoehmBroad Institute of MIT and Harvard
William C HahnBroad Institute of MIT and Harvard
William C HahnDana-Farber Cancer Institute, Harvard Medical School
William C HahnHarvard Medical School
William C HahnBroad Institute of MIT and Harvard
William C HahnHarvard Medical School
William C HahnDana-Farber Cancer Institute, Harvard Medical School
Francisca VazquezBroad Institute of MIT and Harvard
Todd R GolubBroad Institute of MIT and Harvard
Todd R GolubHarvard Medical School
Todd R GolubDana-Farber Cancer Institute, Harvard Medical School
Todd R GolubBroad Institute of MIT and Harvard
Todd R GolubHarvard Medical School
Todd R GolubDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 22

Datasets

Release 1.2